Vimarsana
Biggest News Aggregation in the World

Page 10 - Life Sciences Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Life Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Life Sciences Ltd Today - Breaking & Trending Today

India's Glenmark Pharma reports lower Q4 profit as domestic sales weaken - Vimarsana News

India's Glenmark Pharma reports lower Q4 profit as domestic sales weaken

Consolidated profit before exceptional items and tax fell to $37.78mln for the three months ended March 31

Source: zawya.com
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst - Vimarsana News

Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst

<iframe src=https://www.youtube.com/embed/h8lhg1Y22Ko></iframe>Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage... | May 5, 2023

Glenmark Life Sciences Ltd Q4 FY2022-23 PAT soars to Rs. 146.35 crores - Vimarsana News

Glenmark Life Sciences Ltd Q4 FY2022-23 PAT soars to Rs. 146.35 crores

The Board of Directors of Glenmark Life Sciences Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023.

Tiziana Life Sciences Ltd: Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis - Vimarsana News

Tiziana Life Sciences Ltd: Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis

LONDON, UK / ACCESSWIRE / April 19, 2023 / Tiziana Life Sciences (NASDAQ:TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3

Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Increases By 213.1% - Vimarsana News

Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Increases By 213.1%

Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Rating) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 143,100 shares, a growth of 213.1% from the March 15th total of 45,700 shares. Based on an average daily trading volume, of 83,400 […]

Source: wkrb13.com